Compare Paychex, Inc. (PAYX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs Viatris Inc — how do they compare? Paychex, Inc. trades at $103.98 (market cap $37.19B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Paychex, Inc. is the larger of the two by market cap, and Paychex, Inc. pays the higher dividend (4.56%). Which is the better fit depends on your goals — on Pluang, investors hold Paychex, Inc. for 56 Days and Viatris Inc for 57 Days on average.
| PAYX | VTRS | |
|---|---|---|
Market Cap | $37.19B | $20.03B |
Volume | 3,344,316 | 14,109,977 |
Sector | Industrials | Health |
52-Week High | $128.59 | $18.27 |
52-Week Low | $85.57 | $9.74 |
Typical Hold Time | 56 Days | 57 Days |
Enterprise Value | $40.87B | $32.15B |
Dividend Yield | 4.56% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paychex (PAYX) trades at $104.46, up 2.87% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company continues to deliver strong fundamentals, beating earnings estimates for the last three quarters with a net income margin of 27.35% and robust ROE of 47.06%. Recent news highlights earnings beats but also concerns over stock performance and dividend sustainability despite a recent 5-star rating from Newsweek.
The stock presents a cautious opportunity with a consensus price target of $111 offering ~6% upside, but risks include a high P/E of 20.73, significant debt increase, and sensitivity to labor market trends. Investor sentiment is divided, with analyst consensus leaning Hold, reflecting balanced growth prospects against valuation and macroeconomic headwinds.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.
The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
